Former AXA Framlington Biotechnology fund manager Andy Smith has joined biopharma specialist Mann Bioinvest to launch an income-focused fund in the coming weeks.
The Magna BioPharma Income fund, slated to launch around the end of Q1 2013, will be managed by Smith, with key decisions overseen by an investment committee. Boutique equity house Charlemagne Capital...
Stamp duty reform? Raid on pensions?
Modern and cost-efficient
Joined on 13 November
Published by the Investment Association alongside the Alternative Investment Management Association and the Association for Financial Markets in Europe
Views of tax raises 'overblown'